Antibody-Based Angiogenesis Blocker
A Phase I trial of a monoclonal antibody-based drug which can block theprocess of angiogenesis has now started in the USA. It is thought to be the first time that an antibody has reached the clinic for this indication. Angiogenesis inhibitors are thought to hold promise in the treatment of a range of proliferative diseases, including cancer. The Phase I trial will involve 15 patients with incurable cancer, and is expected to last for approximately one year.
The antibody, Vitaxin, targets the alphav-beta3 receptor on endothelial cells. It is derived from a murine antibody (LM609) and is exclusively licensed by Ixsys Inc of San Diego, USA, from the Scripps Research Institute. Vitaxin has been "humanized" to render it less immunogenic to patients, and therefore more suitable for multiple dosing. LM609 has been shown to decrease blood vessel formation and cause regression of tumors in several animal models.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze